It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Childhood radioactive iodine exposure from the Chornobyl accident increased papillary thyroid carcinoma (PTC) risk. While cervical lymph node metastases (cLNM) are well-recognized in pediatric PTC, the PTC metastatic process and potential radiation association are poorly understood. Here, we analyze cLNM occurrence among 428 PTC with genomic landscape analyses and known drivers (131I-exposed = 349, unexposed = 79; mean age = 27.9 years). We show that cLNM are more frequent in PTC with fusion (55%) versus mutation (30%) drivers, although the proportion varies by specific driver gene (RET-fusion = 71%, BRAF-mutation = 38%, RAS-mutation = 5%). cLNM frequency is not associated with other characteristics, including radiation dose. cLNM molecular profiling (N = 47) demonstrates 100% driver concordance with matched primary PTCs and highly concordant mutational spectra. Transcriptome analysis reveals 17 differentially expressed genes, particularly in the HOXC cluster and BRINP3; the strongest differentially expressed microRNA also is near HOXC10. Our findings underscore the critical role of driver alterations and provide promising candidates for elucidating the biological underpinnings of PTC cLNM.
Childhood radioactive iodine exposure from the Chornobyl accident led to an increased papillary thyroid carcinoma (PTC) risk and potentially higher invasiveness depending on tumour genetic profiles. Here, the authors use genomics to characterise and predict cervical lymph node metastases in PTC patients affected by the Chornobyl accident.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 National Institutes of Health, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 National Institutes of Health, Laboratory of Genetic Susceptibility, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
3 V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine, Laboratory of Morphology of the Endocrine System, Kyiv, Ukraine (GRID:grid.418978.b)
4 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
5 National Institutes of Health, Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
6 National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine (GRID:grid.419973.1) (ISNI:0000 0004 9534 1405)
7 Frederick National Laboratory for Cancer Research, Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Bethesda, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
8 Charing Cross Hospital, Department of Surgery and Cancer, Imperial College London, London, United Kingdom (GRID:grid.413820.c) (ISNI:0000 0001 2191 5195)
9 National Institutes of Health, Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
10 National Institutes of Health, Laboratory of Genetic Susceptibility, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Nvidia Corporation, Santa Clara, USA (GRID:grid.451133.1) (ISNI:0000 0004 0458 4453)
11 Biospecimen Core Resource, Nationwide Children’s Hospital, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476); Ohio State University College of Medicine, Departments of Pathology and Pediatrics, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
12 Biospecimen Core Resource, Nationwide Children’s Hospital, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476)
13 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Massachusetts General Hospital, Center for Cancer Research and Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
14 V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine, Department of Fundamental and Applied Problems of Endocrinology, Kyiv, Ukraine (GRID:grid.418978.b)